Document is current
Any future updates will be listed below
-
Authors
Kitadai, Rui http://orcid.org/0000-0003-0478-9427
Shimoi, Tatsunori http://orcid.org/0000-0002-3603-8575
Yazaki, Shu http://orcid.org/0000-0002-6141-9927
Okuma, Hitomi Sumiyoshi http://orcid.org/0000-0001-9639-7361
Hoshino, Mai
Ito, Munehiro http://orcid.org/0009-0008-4751-6094
Saito, Ayumi http://orcid.org/0000-0001-9302-4287
Kita, Shosuke
Kojima, Yuki http://orcid.org/0000-0002-1558-5510
Nishikawa, Tadaaki http://orcid.org/0000-0003-2606-4208
Sudo, Kazuki http://orcid.org/0000-0002-4600-9428
Noguchi, Emi http://orcid.org/0000-0003-0326-7555
Fujiwara, Yasuhiro http://orcid.org/0000-0002-1229-5446
Yoshida, Masayuki
Yonemori, Kan http://orcid.org/0000-0002-7624-7611
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 8 July 2024
First Online: 14 August 2024
Declarations
:
: T. Nishikawa has a speakers’ bureau for Chugai Pharma, Eisai, Genmab, MSD, Roche Diagnostics, Sanofi, and Takeda and institutional research funding from AstraZeneca and Daiichi-Sankyo. K. Sudo reports receiving grants from Daiichi-Sankyo, AstraZeneca, Amgen, PRA Health Sciences, NanoCarrier, Takeda, Merck, and Gilead. He also reports receiving honoraria for speakers' bureaus and manuscript writing from AstraZeneca, Eisai, Bayer Yakuhin, Pfizer, Nihon Medi-Physics, and MSD. M. Yoshida reports receiving consulting fees from Lilly Japan and Roche Japan. He also reports receiving honoraria for speakers' bureaus and manuscript writing from Agilent technologies, Chugai Pharma, Ono Yakuhin, MSD, and Daiichi-Sankyo. K. Yonemori has a speakers’ bureau for Honorarim for lecture: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR pharma, MSD, Boeringer Ingelheim, Ono, Daiichi-Sankyo, Bayer, Jansen, Asteras, Bristol Myers Squibb, and Sanofi. He is an Advisory board for Eisai, Astra Zeneca, Sanofi, Genmab, Gliad, OncXerna, Takeda, Novartis, MSD, and Henlius. He reports receiving research grants from MSD, Daiichi-Sankyo, Merk Biopharma, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe. He also reports receiving honoraria for lectures, presentations, and speakers' bureaus for Pfizer, Eisai, AstraZeneca, Eli lilly, Takeda, Chugai, MSD, FujiFilm Pharma, Bayer, Asteras, Boehringer Ingelheim, Daiichi-Sankyo, PDR pharma, and Sanofi. He is also a principal investigator for MSD, Daiichi-Sankyo, AstraZeneca, Taiho, Merk Biopharma Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe.
: This study was approved by the Institutional Review Board of the National Cancer Center (Tokyo, Japan) [No. 2014-092]. This study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board owing to the retrospective nature of the study.
